secwatch.observer — SEC 8-K summary
======================================

Issuer:     GoodRx Holdings, Inc. (GDRX)
CIK:        0001809519
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001809519-24-000162
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GoodRx reports Q2 2024 revenue $200.6M, net income $6.7M, adjusted EBITDA $65.4M
--------------------------------------------------------------------------------

- Revenue and Adjusted Revenue of $200.6M for Q2 2024.
- Net income of $6.7M (3.3% margin); Adjusted Net Income of $32.4M (16.1% margin).
- Adjusted EBITDA of $65.4M (32.6% margin).
- Net cash from operations $9.7M; over 7M consumers of prescription offerings.
- Interim CEO Scott Wagner noted progress in retail/PBM partnerships and brand medication scaling.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1809519/000180951924000162/0001809519-24-000162-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1809519/000180951924000162/gdrx-20240808.htm
  HTML page:      https://secwatch.observer/filing/0001809519-24-000162

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer